• 24 August, 2025

Sun Pharma’s Aggrenox gets USFDA nod

August 24, 2018 | Friday | News

This is a generic copy of Boehringer Ingelheim Pharma’s drug Aggrenox (Aspirin/Dipyridamole). Aggrenox and its generics are estimated to have US sales of ~$230mn in the US

Sun Pharma has received final USFDA approval for Aspirin and Dipyridamole. This is a generic copy of Boehringer Ingelheim Pharma’s drug Aggrenox.

 Aggrenox is used to lower the risk of stroke in people who have had a mini-stroke or stroke due to a blood clot.

Aggrenox and its generics are estimated to have US sales of approximately $230mn in the US and with the lower competition, Sun pharma expect to make $8-10mn/annum from this drug.

Comments

× Your session has expired. Please click here to Sign-in or Sign-up
New User? Create Account

Trending Topics

Most Read

Survey Box

Can Policy Reforms & Investments Trigger India’s MedTech Makeover?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls

Have an Account?

Forgot your password?

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy